Resource-adapted immunotherapy bridging to achieve measurable residual disease negativity before allogeneic hematopoietic stem cell transplantation in high-risk acute lymphoblastic leukemia: A single-center real-world experience
International Journal of Molecular and Immuno Oncology · 25.04.2026 · 1-6
DOI: 10.25259/ijmio_12_2026 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular and Immuno Oncology, online erschienen am 25.04.2026. Verfasst von Prashant Mehta und 11 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Objectives
The objective of the study is to describe the feasibility, toxicity, and early transplant outcomes of a structured resource-adapted immunotherapy bridging program using blinatumomab and/or inotuzumab ozogamicin (InO) to achieve measurable residual disease (MRD)-negative status before allogeneic hematopoietic stem cell transplantation (allo-HSCT) in high-risk acute lymphoblastic leukemia (ALL). Material and Methods: This was a retrospective single-center analysis of consecutive high-risk patients with ALL who underwent allo-HSCT between December 2023 and September 2025 (data cutoff: December 14, 2025). Bridging feasibility measures were predefined. Blinatumomab was delivered using a label-supported multi-day infusion with the 7-day bag option, prepared with bacteriostatic 0.9% sodium chloride under pharmacy-supervised aseptic conditions in eligible patients, and age-adapted step-up dosing was used. InO was dose-capped at 0.3 mg/m 2 /dose, same-day scheduling was used, when possible, to facilitate vial sharing, and a planned washout of at least 6 weeks was maintained before allo-HSCT to mitigate sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) risk. End points included feasibility, blinatumomab utilization, toxicity, relapse, overall survival (OS), leukemia-free survival (LFS), non-relapse mortality (NRM), SOS/VOD, transplant-associated thrombotic microangiopathy (TMA), and graft failure.
Results
Nine patients underwent allo-HSCT after MRD-negative bridging. Donors were haplo-identical related in 7 patients and matched siblings in 2. Blinatumomab was used in 6/9 patients (1 cycle in 5; 2 cycles in 1) and InO in 4/9 patients (3 doses each; dose-capped). One multiply relapsed Philadelphia chromosome-positive patient after CAR-T therapy received ponatinib plus asciminib plus InO before transplantation. Median blinatumomab utilization was 14.5 vials/cycle (38.5 mcg), range 6–16. All blinatumomab recipients developed grade 1 cytokine release syndrome, and 1 patient developed grade 3 immune effector cell-associated neurotoxicity syndrome with seizure. At the cutoff, relapse occurred in 2/9 patients, with 1 death after relapse. The estimated 1-year Kaplan– Meier OS was 100%, and the estimated 1-year Kaplan–Meier LFS was 70%. NRM, SOS/VOD, and graft failure were each 0%, and TMA occurred in 1/9 patients.
Conclusion
A structured feasibility-focused bridging program combining label-supported 7-day blinatumomab infusion bags, age-adapted step-up dosing, and dose-capped InO with vial sharing and a transplant washout strategy enabled MRD-negative allo-HSCT in all transplanted patients in this small real-world high-risk ALL cohort. The approach showed encouraging early survival with no NRM or SOS/VOD and supports prospective evaluation of resource-conscious immunotherapy implementation in transplant-eligible ALL.
Zitieren
APA
Mehta, P., Baghmar, S., Pabbi, S., Singh, A., Kapoor, V., Das, N., Suryavanshi, M., Kumar, R., Gupta, K., Katharia, R., Jain, A., & Kaur, J. (2026). Resource-adapted immunotherapy bridging to achieve measurable residual disease negativity before allogeneic hematopoietic stem cell transplantation in high-risk acute lymphoblastic leukemia: A single-center real-world experience. International Journal of Molecular and Immuno Oncology, 0, 1-6. https://doi.org/10.25259/ijmio_12_2026
Vancouver
Mehta P, Baghmar S, Pabbi S, Singh A, Kapoor V, Das N, et al. Resource-adapted immunotherapy bridging to achieve measurable residual disease negativity before allogeneic hematopoietic stem cell transplantation in high-risk acute lymphoblastic leukemia: A single-center real-world experience. International Journal of Molecular and Immuno Oncology. 2026;0:1-6. doi:10.25259/ijmio_12_2026
BibTeX
@article{Mehta2026,
author = {Mehta, Prashant and Baghmar, Saphalta and Pabbi, Swati and Singh, Ankita and Kapoor, Vidit and Das, Nupur and Suryavanshi, Moushumi and Kumar, Rahul and Gupta, Kusum and Katharia, Rahul and Jain, Anshul and Kaur, Jagsahib},
title = {Resource-adapted immunotherapy bridging to achieve measurable residual disease negativity before allogeneic hematopoietic stem cell transplantation in high-risk acute lymphoblastic leukemia: A single-center real-world experience},
journal = {International Journal of Molecular and Immuno Oncology},
year = {2026},
volume = {0},
pages = {1--6},
doi = {10.25259/ijmio_12_2026}
}
EUVIMED